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Background: DrrAB is dedicated to export of 
doxorubicin in Streptomyces peucetius, an 
organism which produces this anticancer drug.  
Whether this prototype system can export other 
drugs has not been investigated. 
Results: DrrAB exports multiple drugs efficiently. 
Conclusion: Substrate specificity of DrrAB 
overlaps with known bacterial and human multi-
drug resistance proteins. 
Significance: This study suggests common 
mechanisms and origin for DrrAB and other MDR 
proteins. 
 
ABSTRACT 
The soil bacterium Streptomyces 
peucetius produces two widely used anticancer 
antibiotics doxorubicin and daunorubicin.  
Present within the biosynthesis gene cluster in 
S. peucetius is the drrAB operon which codes 
for a dedicated ABC-type transporter for the 
export of these two closely related antibiotics.  
Because of its dedicated nature, the DrrAB 
system is believed to belong to the category of 
single-drug transporters.  However, whether it 
also contains specificity for other known 
substrates of multidrug transporters has never 
been tested.  In this study, we demonstrate 
under both in vivo and in vitro conditions that 
the DrrAB system can transport not only 
doxorubicin but is also able to export two most 
commonly studied MDR substrates, Hoechst 
33342 and ethidium bromide.  Moreover, we 
demonstrate that many other substrates 
(including verapamil, vinblastine, and 
rifampicin) of the well-studied multi-drug 
transporters inhibit DrrAB-mediated Dox 
transport with high efficiency, indicating that 
they are also substrates of the DrrAB pump.  
Kinetic studies show that inhibition of 
doxorubicin transport by Hoechst 33342 and 
rifampicin occurs by a competitive mechanism 
whereas verapamil inhibits transport by a non-
competitive mechanism, thus suggesting the 
possibility of more than one drug binding site in 
the DrrAB system.  This is the first in-depth 
study of a drug resistance system from a 
producer organism, and it shows that a 
dedicated efflux system like DrrAB contains 
specificity for multiple drugs.  The significance 
of these findings in evolution of poly-specificity 
in drug resistance systems is discussed.   
Multidrug resistance (MDR) has emerged 
as a major clinical problem in recent years both for 
the treatment of infectious diseases and for 
chemotherapy of cancer.  Although many different 
mechanisms for drug resistance are known, a 
common strategy consists of active efflux of drugs 
from the cells (1).  Drug transporters are 
categorized into either single-drug efflux systems 
(which are specific for a drug or a group of drugs) 
or multi-drug efflux systems that exhibit a broad 
specificity and can transport structurally and 
functionally unrelated compounds.  These proteins 
function as either primary active (belonging to the 
ATP Binding Cassette superfamily) or secondary 
active transporters (2).  The phenomenon of 
multidrug resistance was first characterized in 
mammalian cancer cells, where exposure to 
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anticancer drugs was seen to result in over-
expression of ABC-type efflux pumps, such as P-
glycoprotein and MRP1 (2).  These proteins have 
since been shown to transport hundreds of 
structurally unrelated compounds, including 
amphipathic anti-cancer drugs, peptides, and 
fluorescent dyes, etc., thus conferring MDR in 
cancer cells.  MDR is also widespread among 
bacteria - the best known ABC family members 
include the bacterial proteins LmrA and LmrCD in 
L. lactis, Sav1866 in S. aureus, and MsbA in E. 
coli.   
While most of the ABC proteins 
mentioned above have served as useful models to 
characterize and understand the basis of MDR 
(2,3), the most extensive biochemical analysis of 
the nature of multidrug specificity has been carried 
out with Pgp (4,5).  Together the analyses carried 
out by many different groups suggested that Pgp 
contains a large drug binding chamber which can 
accommodate several drugs simultaneously. It was 
also suggested that the drug binding chamber in 
Pgp is lined by several trans-membrane (TM) 
helices, including TMs 4-6 in TMD1 and TMs 9-
12 in TMD2 (4).  Most recently, the crystal 
structure of Pgp confirmed many findings of the 
biochemical analysis and showed that Pgp indeed 
contains a large and flexible drug binding cavity 
made of mostly hydrophobic and aromatic 
residues (6).  Different drugs were seen to interact 
with residues in different parts of the flexible 
cavity, mostly through hydrophobic interactions, 
thus providing an explanation for the poly-specific 
nature of Pgp.  The crystal structure of Pgp also 
revealed that some drugs were bound to a single 
site, while some others bound to two different 
locations within the cavity.  The drug binding 
cavity of Pgp was found to reside within the cell 
membrane, and it showed the presence of two 
portals formed by TMs 4 and 6 and TMs 10 and 
12 which allow direct entry of hydrophobic 
molecules from the membrane (6).  This 
observation supports previous models, which 
proposed that Pgp can extract drugs directly from 
the lipid bilayer and remove them by a 
hydrophobic vacuum cleaner mechanism (7).  The 
crystal structure of another MDR protein, AcrB, a 
secondary-active transporter, is also available.  
This structure also showed the presence of a very 
large central drug binding cavity, which could 
accommodate several ligand molecules 
simultaneously (8).  However, the drug binding 
cavity, though present in the membrane, was 
found to be accessible to the periplasmic domain.  
Thus, in contrast to Pgp (where the drug portals 
are located in the membrane), the periplasmic 
region of AcrB seems to play a major role in 
determining substrate specificity, suggesting 
differences between the mechanisms of different 
MDR proteins. 
The bacterial ABC drug transporters that 
have also been studied in significant detail include 
the E. coli ABC transporter MsbA (responsible for 
export of Lipid A, the core moiety of LPS), L. 
lactis homologue LmrA and S. aureus Sav1866 
(3,9,10).  All of these proteins have been shown to 
transport multiple drugs.  Interestingly, MsbA was 
found to contain overlapping substrate specificity 
with LmrA and Sav1866 (11).  Some newly 
identified members, such as VcaM from Non-O1 
Vibrio cholerae and the YccC (BmrA) from 
Bacillus subtilis were also shown to transport 
multiple drugs (12,13).  Therefore, a significant 
progress has indeed been made in understanding 
the phenomenon of multidrug resistance.  
However, the available information is based on the 
analysis of only a handful of drug transporters 
described above.  Most other annotated drug 
transporters, especially those found in the 
antibiotic/drug producer organisms, have not been 
analyzed for their ability to confer MDR.  
Moreover, not much is known about why and how 
the ability to confer multidrug resistance evolves.   
In this study, we analyzed the ABC 
transporter DrrAB, which confers self-resistance 
to two related anticancer antibiotics doxorubicin 
(Dox) and daunorubicin (Dnr) in the producer soil 
organism Streptomyces peucetius.  The genes for 
this system are present in an operon located within 
the gene cluster for biosynthesis of Dox and Dnr, 
therefore they code for a dedicated transporter for 
these antibiotics.  The DrrAB system represents 
the simplest form of an ABC drug transporter, 
which is assembled from two molecules each of 
DrrA (the catalytic subunit) and DrrB (integral 
membrane subunit) (14).  In the mammalian Pgp, 
the two catalytic and two integral membrane 
domains are naturally fused into a single large 
polypeptide, possibly the result of an evolutionary 
gene fusion event (15).  Both DrrAB and Pgp 
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confer resistance to the anticancer agents Dox and 
Dnr: DrrAB in the producer organism and Pgp in 
cancer cells.  Therefore, the overall structure and 
function of the DrrAB transporter bears significant 
similarity to Pgp even though these two 
transporters belong to different classes of ABC 
proteins (16).   Subcloning of the drrAB locus in 
E. coli was previously shown to confer 
doxorubicin resistance in this host (17).  It was 
also previously shown that the DrrAB system 
confers resistance to Dox by an energy-dependent 
efflux mechanism (18).  However, it is not known 
if this system is specific for Dox and Dnr, or if, 
like Pgp, it can also recognize and transport 
multiple drugs.  Since this is a prototype drug 
resistance mechanism found in the producer 
organism, analysis of this system could shed light 
on the nature of substrate specificity and elucidate 
how the ability to confer multidrug resistance 
evolves in proteins.   
In this paper, we provide in-depth 
characterization of drug transport by the DrrAB 
system and show that, contrary to the generally 
held assumption, this system forms a multidrug 
transporter.  Using both E. coli whole cells and 
inside-out membrane vesicles (IOVs), it is shown 
that the DrrAB system can efficiently transport not 
only Dox, but also Hoechst 33342 (H 33342) and 
ethidium bromide (EtBr), two substrates most 
commonly used to establish the MDR phenotype 
(3,10,19).  We also found that the DrrAB-
mediated Dox efflux is inhibited by a number of 
other well-characterized MDR substrates, such as 
verapamil, rifampicin, vinblastine and colchicine, 
suggesting that these drugs are also substrates of 
the DrrAB pump.  Interestingly, DrrAB-mediated 
efflux could be coupled to the energy of either 
ATP or GTP hydrolysis, and, as expected, the 
function of this transporter was found to be 
completely independent of the proton motive force 
(pmf).  Since multiple drugs were found to inhibit 
Dox efflux by the DrrAB system, kinetics analysis 
was carried out to understand the mechanism of 
inhibition and interaction of drugs with DrrAB.  
Our studies revealed that inhibition of Dox efflux 
by H 33342 and rifampicin occurs by a 
competitive mechanism, whereas verapamil 
inhibits Dox transport by a non-competitive 
mechanism, suggesting that the DrrAB transporter 
may contain at least two drug binding sites.  The 
findings of this paper demonstrate for the first time 
that the dedicated Dox transport system, DrrAB, 
can recognize and transport multiple drugs.  This 
study highlights overlaps between the substrate 
specificity of the DrrAB system and Pgp and 
points to a common mechanism, and perhaps 
origin, for most MDR proteins. 
 
EXPERIMENTAL PROCEDURES 
Materials used – verapamil, vinblastine, 
rifampicin, doxorubicin hydrochloride, ethidium 
bromide, quinine, quinidine, colchicine, succinate, 
sodium fluoride, NADH (β-Nicotinamide adenine 
dinucleotide reduced disodium salt hydrate), ATP, 
GTP, and sodium o-vanadate were purchased from 
Sigma Aldrich.  Hoechst 33342, rhodamine 123, 
rhodamine 6G, rhodamine B, and TMRM 
(Tetramethyl rhodamine) were obtained from Life 
Technology.  Creatine kinase and creatine 
phosphate were purchased from Roche 
Diagnostics.  
In vivo Dox efflux in cells – E. coli 
LE392ΔuncIC cells (Table 1) containing either 
vector pSU2718 or pDX101(pSU2718/drrAB) 
were grown in 200 ml TEA medium [50 mM 
triethanolamine HCl, pH 6.9, 15 mM KCl, 10mM 
(NH4)2SO4, 1mM MgSO4] supplemented with 
0.5% (w/v) glycerol, 2.5 µg/ml thiamine, 0.5% 
(w/v) peptone and 0.15% (w/v) succinate to mid-
log phase and induced with 0.1 mM IPTG for 1 hr.  
The harvested cells were washed twice and 
resuspended in 100 µl TEA buffer.  10 μl of the 
cell suspension from above was incubated in 3 ml 
of TEA medium containing 10 μM doxorubicin 
and 5 mM 2,4-dinitrophenol for 11 h at 37 °C.  
The loaded cells were washed twice with 0.1 mM 
MOPS buffer, pH 7.0 and resuspended in 3 ml of 
MOPS buffer containing 2 mM MgSO4.  The 
fluorescence spectra were recorded on an 
Alphascan-2 spectrofluorometer (Photon 
Technology International, London, Ontario, 
Canada).  The excitation wavelength for 
doxorubicin was 480 nm, and emission was 
monitored at 590 nm.  The excitation and emission 
slit widths were both set at 1.00 mm, and a time-
based script was run.  After an initial recording of 
fluorescence for 100 s at 37 °C, energy was 
provided in the form of either 20 mM glucose or 
20 mM succinate, and recording was continued for 
an additional 400 s.  The rate of Dox efflux was 
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determined from the slope in the steady-state 
range (300 s to 500 s).  Where indicated, 10 mM 
sodium fluoride was added as inhibitor of ATP 
synthesis. 
In vivo ethidium bromide efflux in cells – 
E. coli LE392ΔuncIC cells containing the 
indicated plasmid were grown, induced, and 
loaded with various concentrations (1 µM to 100 
µM) of EtBr, as described above, except that the 
loading time used was 1 hr at 37 °C.  The loaded 
cells were washed twice with 0.1 mM MOPS, pH 
7.0 and resuspened in 3 ml MOPS buffer 
containing 2 mM MgSO4.  EtBr efflux from 
loaded cells was measured fluorometrically (exi, 
500 nm; emi, 580 nm) on an Alphascan-2 
spectrofluorometer (Photon Technology 
International).   After 100 s, energy was provided 
in the form of 20 mM glucose.  The recording was 
continued for additional 400 s.  The rate of EtBr 
efflux was determined from the slope in the 
steady-state range (300 s to 500 s).   
Preparation of inside-out membrane 
vesicles (IOVs) – E. coli LE392ΔuncIC cells 
containing indicated plasmids were grown in 1 L 
LB medium at 37 °C until mid-log phase and 
induced with 0.25 mM IPTG at 37 °C for 3 hr.  
The cells pellet was re-suspended in 20 ml 1xPBS 
buffer, pH 7.4 and lysed with French Press at 
16,000 p.s.i. twice.  The membrane fraction was 
prepared according to the previously published 
protocol (14), except that the membrane vesicles 
were washed twice with 20 ml 1xPBS buffer.   
In vitro Dox efflux in IOVs and kinetic 
analysis – 250 µg IOVs were resuspended in 3 ml 
1x PBS buffer, pH 7.4 supplemented with 0.1 
mg/ml creatine kinase and 5 mM creatine 
phosphate.  Dox was added to a final 
concentration of 1.0 µM, or as indicated.  The 
fluorescence spectra were recorded on an 
Alphascan-2-spectrofluorometer with excitation 
wavelength of 480 nm and emission wavelength of 
590 nm.  The excitation and emission slit width 
were set to 1.00 mm and data were collected at 
0.1-s intervals.  After 100 s, the detection was 
paused, 1 mM Mg
2+
 and 1 mM ATP, pH7.5 were 
added into the reaction and the detection was 
continued for additional 400 s.  Where indicated, 
ATP was substituted with 1 mM GTP or 5 mM 
NADH.  The rate of Dox transport was determined 
from the slope of the initial linear range between 
100 s and 200 s.  To determine the kinetics of Dox 
transport, efflux was measured at a wide range of 
Dox concentrations (0.1 µM to 6 µM).  The data 
were fitted by the Michaelis–Menten equation (V 
= Vmax[S]/(Km) + [S]) by Sigma Plot Kinetics 
software in Single-Substrate Format.  
In vitro Hoechst 33342 Efflux in IOVs – 
The DrrAB-mediated efflux of H 33342 was 
studied in IOVs, as described above for Dox 
Efflux with some modifications.  Briefly, 250 µg 
IOVs were resuspended in 3 ml 1x PBS buffer, pH 
7.4 supplemented with 0.1 mg/ml creatine kinase 
and 5 mM creatine phosphate and various 
concentrations of H 33342 (0.1 µM to 2.5 µM).  
The excitation and emission wavelengths of H 
33342 were 355 nm and 457 nm, respectively.  
The rate of H 33342 transport was determined 
from the initial slope of the linear range 
between100 s to 200 s.   
Vanadate inhibition of Dox efflux in IOVs 
– 250 µg IOVs were resuspended in 3 ml 1x PBS 
buffer, pH 7.4 supplemented with 0.1 mg/ml 
creatine kinase, 5 mM creatine phosphate, 1 µM 
Dox, and various concentrations of sodium o-
vanadate (0 µM – 100 µM).  The measurement of 
Dox efflux was performed, as described above.  
The rate of Dox transport was determined from the 
slope of the linear range between 100 s and 200 s.   
Determination of IC50 – 250 µg IOVs were 
resuspended in 3ml 1xPBS buffer, pH 7.4 
supplemented with 0.1 mg/ml creatine kinase and 
5 mM creatine phosphate, 1 µM Dox, and various 
concentrations of the inhibitory drug.  The 
measurement of Dox efflux was performed, as 
described above.  The rate of Dox transport was 
determined from the slope of the initial linear 
range between 100 s and 200 s.  Designating the 
efflux rate of the sample without inhibitor as 1.0, 
the relative rate of each sample was calculated.  
The average data of three independent experiments 
were plotted by ‘Scatter Plot with simple error 
bars’ in Sigma Plot 11.0 software and fitted by the 
dynamic curve fit (equation: y = ae
-bx
, x: 
concentration of inhibitor; y: relative rate).  The 
IC50 value was determined based on the 
concentration of the drug that brings about 50% 
inhibition of the DrrAB-mediated Dox efflux at a 
Dox concentration of 1 µM.  
Kinetics of Dox efflux inhibition by known 
MDR substrates – To study the kinetic inhibition 
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of Dox efflux by H 33342, four different 
concentrations of Dox (0.25, 0.5, 0.75 and 1.0 µM) 
were individually mixed with a fixed 
concentration of H 33342 in 1x PBS buffer 
containing 250 µg IOVs, 0.1 mg/ml creatine 
kinase and 5 mM creatine phosphate.  In total, four 
different concentrations of H 33342 (0, 0.2, 0.6 or 
0.8 µM) were studied.  Similar assays were set up 
to study kinetics of Dox inhibition by different 
drugs.  Initial rate of Dox transport was 
determined, as described above.  The rate of Dox 
transport obtained with 1 µM Dox and 0 µM H 
33342 (or another drug) was designated as 1.0. 
The relative rates were then calculated for each 
efflux curve, and the data were plotted by 
Lineweaver-Burk plot using SigmaPlot - Kinetics 
software in Single-Substrate/Single-Inhibitor 
Kinetics Format.  The error bars represent three 
independent experiments.  The type of inhibition 
was determined based on the AICc value (Akaikes 
Information Criterion corrected); lower AICc 
values correspond to better fits to the data.   
Point Mutations in DrrA – Site-directed 
mutagenesis of the drrA gene was carried out by a 
QuikChange Multisite-directed mutagenesis kit 
(Stratagene, La Jolla, CA). Using pDX101 
(pSU2718/drrAB) plasmid as the template, Gln197, 
located in the Switch motif of DrrA, was changed 
to Histidine. The resulting plasmid was named 
pDX101(Q197H).  Another plasmid, generated by 
substituting Tyr198 to Arginine, was named 
pDX101(Y198R).  Double mutations of 
Gln197Tyr198 to His197Arg198
 
and
 
His197His198
 
were also created, and these 
plasmids were named pDX101(Q197H/Y198R; 
HR) and pDX101(Q197H/Y198H; HH).  Other 
mutations used in this study were described 
previously (Table 1). 
ATPase activity in IOVs - 7.5 µg IOVs 
expressing either wild type DrrAB or DrrAB with 
mutations in the Switch motif were incubated in 1 
ml reaction mixture containing 50 mM MOPs, pH 
7.5, 1mM dithiothreitol, 10µl PK/LDH enzyme 
(Sigma Aldrich), 5 mM ATP, 0.25 mM NADH (β-
Nicotinamide adenine dinucleotide) and 1.25 mM 
PEP[phosphor(enol)pyruvic acid] at 37 ºC for 10 
min, as described previously (20).  The reaction 
was started by addition of 2.5 mM MgCl2.  The 
optical density at 340 nm was monitored for 10 
min using Shimadzu UV1601 spectrophotometer 
and the UV probe 2. 20 Kinetics software.  The 
slope of the linear portion of each curve (between 
200 s and 400 s) was used to calculate ATPase 
activity.  The activity of the control IOVs (without 
DrrAB) was subtracted from the activity of each 
test sample to obtain DrrAB-specific activity.  
Relative activity was then calculated by dividing 
the activity of each sample by the activity of the 
wild type sample.   
 
RESULTS 
Characterization of the DrrAB-mediated 
Dox efflux under in vivo and in vitro conditions – 
An in vivo assay for studying DrrAB-mediated 
Dox efflux was reported previously (18,21) and is 
shown in Fig. 1A.  In this study, we established 
conditions to study DrrAB-mediated Dox efflux 
under in vitro conditions using E. coli inside out 
membrane vesicles (IOVs) (Fig. 1B).  Both in vivo 
and in vitro assays utilize the fluorescent nature of 
Dox to measure efflux in E. coli LE392ΔuncIC 
cells (or IOVs).  This strain of E. coli contains a 
deletion in the unc genes; as a result it is unable to 
carry out synthesis of ATP using proton gradients 
or establish a proton gradient by hydrolysis of 
ATP (22).  Therefore, it is possible to establish 
conditions where only the proton motive force 
(pmf) or ATP is available as a source of energy 
(described below).  Dox is fluorescent in solution, 
however its accumulation inside the cells results in 
quenching of its fluorescence and its efflux results 
in an increase in fluorescence intensity (23). 
In vivo Dox efflux – The basic strategy for 
studying efflux under in vivo conditions consists 
of loading of the de-energized cells with Dox (18), 
followed by addition of an energy source, which is 
expected to result in efflux of Dox and an increase 
in its fluorescence (Fig. 1A).  Under the conditions 
used in our experimental system, use of succinate 
as energy will generate only proton motive force 
while glucose will generate both pmf and ATP, 
therefore allowing us to discriminate between the 
energy sources used by the DrrAB system.  The 
data in Fig. 1A compare the rate of Dox efflux in 
DrrAB-containing cells in the presence of glucose 
or succinate.  E.coli LE392ΔuncIC cells 
(containing empty vector) were used as negative 
control in these experiments.  Two conclusions 
can be made from the data shown in Fig. 1A.  First, 
the rate of Dox efflux by the DrrAB-containing 
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cells in the presence of glucose is about 5-fold 
higher as compared to the rate in control cells (Fig. 
1A.2, compare columns 1 and 4). A small increase 
in Dox efflux efficiency seen in control cells on 
addition of glucose is likely due to the action of 
one of the several MDR pumps known to be 
present in E. coli (1).  Secondly, in contrast to 
glucose, use of succinate as energy showed no 
increase in fluorescence intensity in DrrAB-
containing cells (Fig. 1A.1, curve 2; Fig. 1A.2, 
column 2), indicating that pmf does not support 
Dox efflux by the DrrAB proteins.  Confirmation 
of these results was obtained by addition of 
sodium fluoride, a specific inhibitor of ATP 
synthesis by substrate-level phosphorylation, to 
DrrAB-containing cells in the presence of glucose.  
The data show a drastic reduction in Dox efflux by 
the DrrAB-containing cells (Fig. 1A.1, curve 3; 
Fig. 1A.2, column 3), resulting in the same 
background levels of efflux as seen with succinate 
(column 2).  These studies show that doxorubicin 
efflux by the DrrAB pump is solely ATP-
dependent, and pmf is not required for this process, 
thus highlighting similarities between DrrAB and 
other MDR proteins of the ABC superfamily 
(19,24,25). 
In vitro Dox efflux – To understand the 
kinetics of Dox transport, an in vitro Dox efflux 
assay was optimized using inside-out membrane 
vesicles, as described under Methods.  In this 
assay, the vesicles were mixed with Dox, and 
efflux was initiated by addition of ATP and Mg
2+
.  
Because of the inverted nature of the IOVs, 
DrrAB-mediated efflux results in accumulation of 
Dox inside the vesicles which is seen as quenching 
of its fluorescence (Fig. 1B.1).  The data in Fig. 
1B.1 show that addition of ATP/Mg
2+ 
first results 
in a rapid non-specific decrease in Dox 
fluorescence due to interaction between Dox and 
ATP (23).  This quick phase is then followed by a 
slower rate of quenching, which corresponds to the 
DrrAB-dependent efflux in the vesicles.  The 
initial rate of Dox efflux was therefore determined 
from the linear slope of the fluorescence spectra 
between 100 s and 200 s.  As seen in Fig.1B.1 and 
1B.2, Dox transport activity in vesicles containing 
DrrAB was found to be almost 12-fold higher as 
compared to the control vesicles prepared from 
cells containing vector alone (Fig. 1B.2, compare 
columns 1 and 4).  Absence of either Mg
2+
 
(column 2) or ATP (column 3) resulted in the 
failure of these vesicles to transport Dox.  Use of 
NADH as an energy source also did not support 
Dox efflux (column 6), once again confirming that 
proton motive force is not used by the DrrAB 
proteins as a source of energy.  Surprisingly, when 
GTP was used as an energy source instead of ATP, 
even higher transport activity was observed 
(column 5).  Dox-dependent ATP and GTP 
binding to DrrA was shown previously (17).  
Together these data indicate that either ATP or 
GTP (and Mg
2+
) can serve as a source of energy 
for the Dox transport function of DrrAB. 
Kinetic Analysis of Dox efflux in vitro –To 
understand the kinetics of Dox efflux by the 
DrrAB system, efflux was analyzed (as shown in 
Fig. 1B.1) at a wide range of Dox concentrations.  
The initial rate (slope between 100 s-200 s) of 
each efflux curve was determined.  Efficiency of 
Dox efflux was then calculated, as described under 
Methods and Figure Legends.  The data were 
fitted to a hyperbola using the Michaelis-Menten 
equation (with an R
2
 of 0.89), yielding an apparent 
Km of 0.38 µM and Vmax of 1003 (arbitrary units, 
a.u.) (Fig. 1C).  These data showed a linear 
increase in the rate of Dox transport at 
concentrations ranging between 0.1 µM and 1 µM, 
which became saturated after 3µM.  The Dox 
transport data could also be fitted equally well by 
the Hill equation; the implication of this finding is 
discussed later. 
Inhibition of Dox transport activity by 
sodium o-vanadate – Vanadate (Vi) is a known 
inhibitor of the ATPase activity of ABC proteins 
(26-29).  Since it functions as an analog of Pi, the 
ADP·Vi·Mg
2+ 
complex is trapped in the ATP 
binding pocket after a single catalytic turnover, 
thus blocking further hydrolysis of ATP as well as 
drug transport.  To determine if the DrrAB system 
is inhibited by vanadate, Dox transport was 
measured in IOVs in the absence or presence of 
increasing amounts of vanadate (5 µM to 100 µM).  
The data in Fig. 1D show that vanadate is a potent 
inhibitor of the Dox transport of DrrAB, with an 
IC50 = 11 µM.  A complete inhibition of the Dox 
transport activity was seen at 100 µM vanadate.  
These data are consistent with the previously 
reported studies on the inhibitory effect of 
vanadate on Pgp and MsbA (28,30).  
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Point mutations in the nucleotide binding 
domain (NBD) of DrrA compromise Dox 
transport activity – The N-terminal nucleotide 
binding domain of DrrA contains a 200 amino 
acids long ABC cassette consisting of all the 
conserved motifs (Walker A, Walker B, Signature 
motif/C-loop, Q-loop, and the Switch motif/H-
loop) involved in ATP binding and hydrolysis (Fig. 
2A.1).  We previously reported that mutations in 
the conserved residues of DrrA confer Dox 
sensitivity (31).  Mutations in Walker A, as 
expected, also compromised ATP binding (31).  
Here we evaluated the effect of several mutations 
on DrrAB-mediated Dox efflux in IOVs.  The data 
in Fig. 2B show that, as expected, single point 
mutations in Walker A (such as G44A, G44S or 
K47R), signature (S141R), or the Walker B 
(E165Q) motif of DrrA result in a drastic effect on 
Dox transport activity.  Since the sequence of the 
Switch motif of DrrA is different from most other 
ABC proteins (Fig. 2A), this region was analyzed 
in greater detail, as described below.  Most ABC 
proteins normally contain a highly conserved 
histidine residue in their Switch motif, followed by 
an arginine, histidine, or a lysine (Fig. 2A.1).  The 
conserved histidine of the Switch motif and a 
conserved glutamate immediately following the 
Walker B motif (both are shown as highlighted 
areas in Fig. 2) are together believed to be critical 
for formation of the active sites in ABC proteins.  
Zaitseva et al recently proposed that these two 
residues together form a catalytic dyad which 
functions in substrate-assisted catalysis (32).  
However, despite the high conservation of these 
two residues in ABC proteins, deviations in the 
sequence of these motifs are sometimes seen.  
Most commonly, a glutamine replaces the 
histidine in the Switch motif and an aspartate 
replaces the glutamate in the Walker B region.  
When present (for example, in TAP1 and LmrC), 
these deviations are seen to result in asymmetrical 
ATP binding pockets with one site being 
catalytically non-functional (33,34).  Interestingly, 
however, despite the presence of the non-
canonical glutamine residue (Q197 followed by 
Y198, resulting in QY sequence) in the Switch 
motif of DrrA (and its close prokaryotic homologs, 
Fig. 2A.2), it is able to form a functional drug 
transporter with DrrB, as seen in Fig. 1.  Note that 
the close eukaryotic homologs of DrrA most often 
contain an HH sequence in the Switch region (Fig. 
2A.3), and both prokaryotic and eukaryotic  
homologs contain the conserved glutamate in the 
Walker B region (specifically E165 in DrrA) (Figs. 
2A.2 and 2A.3)   
Since histidine is conserved in the Switch 
of most ABC proteins, we wondered if the DrrAB 
transporter will become more efficient if Q197 is 
substituted with a histidine or if the QY sequence 
is changed to the commonly occurring sequence 
HR or HH.  Surprisingly, we found that the 
Q197H mutation in DrrA produces a drastic effect 
on Dox efflux, however mutation of Y198 to 
Y198R retains about 35% Dox efflux function 
(Fig. 2C).  Interestingly, a double mutation HR 
(Q197H/Y198R) also resulted in Dox transport 
activity of about 38% indicating that the second 
mutation partially masked the harmful effect of the 
Q197H single mutation (Fig. 2C).  By contrast, the 
double mutation HH (Q197H/Y198H) exhibited 
extremely low Dox efflux (Fig. 2C).  To 
understand the role of Q197 and Y198 in catalysis, 
the effect of the above-mentioned mutations on the 
ATPase activity of the DrrAB complex was 
determined.  We found that while Q197H 
produces a drastic effect on ATPase activity, both 
HR and HH double mutations show significant 
ATPase activity (43% and 61%, respectively) 
(Figs. 2D and 2E), indicating that the second 
mutation in each case partially compensates for 
the negative effect of the Q197H mutation on 
catalysis.  Overall the findings in Fig. 2 indicate 
that residues Q197 and Y198 in the Switch motif 
of DrrA function together and that the QY 
sequence works much better than the HH or HR 
sequence for the overall Dox efflux function of the 
DrrAB complex.  Interestingly, the HH double 
mutant still exhibits 60% ATP hydrolysis activity, 
which suggests that either the QY or the HH 
sequence could participate in the formation of 
functional catalytic sites in DrrA.  However, the 
HH allele seems to be defective in specific 
communication between DrrA and DrrB resulting 
in significantly reduced Dox efflux (less than 5%).  
Therefore the context in which the Switch motif 
functions in different ABC proteins may determine 
the nature of this motif.  The conserved glutamate 
E165 present near the Walker B region in DrrA 
served as a control in these experiments.  Analysis 
of the E165Q mutation showed a drastic effect on 
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both hydrolysis of ATP and Dox efflux (Figs. 2B-
D), which is consistent with the critical role of this 
residue previously reported in literature (35).  How 
a glutamine residue participates in the formation 
of functional ATP binding pockets in DrrA is still 
an open question.  However, we can draw from the 
analogous situations present in other ATP/GTP-
binding proteins (including RecA and H-ras p21) 
which contain a catalytic glutamine residue (Q194 
in RecA and Q61 in H-ras p21) in their switch II 
domain in the position corresponding to Q197 in 
DrrA (36-38).  The 3-d structures of RecA and H-
ras indicate that these glutamines show similar 
interactions with the catalytic glutamate and γ 
phosphate of ATP to those seen with histidine in 
the ABC proteins, therefore suggesting that the 
glutamine functions in a manner similar to 
histidine in producing the overall conformation of 
the active site.  This is consistent with our 
observation that either QY or HH sequence can 
indeed participate in formation of the catalytic 
sites in DrrA although the HH sequence is 
deficient in energy transduction.  In summary, the 
analyses in Fig. 2 confirm that a functional 
nucleotide binding domain of DrrA is essential for 
Dox efflux by the DrrAB system.  The analysis of 
the Switch mutations, in particular, also indicates 
that the in vitro efflux assay described here can 
provide a sensitive and a valuable approach for 
elucidating the role of critical residues in the 
catalytic and drug transport function of the DrrAB 
complex.   
DrrAB-mediated Dox efflux is inhibited 
by multiple MDR substrates – To determine if the 
DrrAB transporter can recognize and bind other 
known MDR substrates, inhibition of Dox efflux 
by different drugs was investigated in IOVs.  
These assays were carried out at a wide range of 
the inhibitor concentrations while maintaining a 
constant concentration of Dox, as described under 
Methods (determination of IC50 values).  The data 
in Fig. 3 show that many known MDR drugs, 
including H 33342 (Fig. 3A), verapamil (Fig. 3B), 
and rifampicin (Fig. 3C), inhibit DrrAB-mediated 
Dox efflux with high efficiency.  The data in Fig 3, 
panel D, summarize the inhibitory effects of many 
different MDR substrates and indicate that the IC50 
values vary dramatically for different substrates. 
For example, H 33342, vinblastine, verapamil and 
rifampicin show relatively low IC50 values, while 
much higher concentrations of EtBr, quinidine, 
and colchicine were required for the same level of 
inhibition.  These data suggest that the DrrAB 
system has multiple substrates, which bind with 
varying affinities. However, whether these drugs 
bind to the same site, or if there are multiple drug 
binding sites, can’t be ascertained from these data.  
To understand the nature of drug binding, kinetics 
of DrrAB-mediated Dox efflux was studied at 
multiple Dox concentrations in the presence of 
several concentrations of each inhibitory drug, 
which is described below.  
Kinetics of Dox Inhibition by MDR drugs 
– The data in Fig. 1C showed that the rate of Dox 
efflux by DrrAB-containing IOVs increases 
linearly between 0.1 µM and 1 µM Dox 
concentration, therefore four evenly distributed 
concentrations of Dox within this range (0.25, 0.50, 
0.75, and 1.0 µM) were used in the kinetics 
analysis.  At each concentration of Dox, efflux 
was measured in the presence of our different 
concentrations of H 33342, verapamil, or 
rifampicin.  These drugs were chosen based on 
their low IC50 values seen in inhibition studies 
(Fig.3D).  (Since Dox and EtBr together were 
incompatible in the fluorescence-based assays due 
to their overlapping excitation/emission spectra, 
this combination could not be used in this study).  
The initial slope (100-200 seconds) for each Dox 
efflux curve was determined.  The slope of the 
Dox efflux curve at 1.0 µM Dox and 0 
concentration of the inhibitor was designated as 1, 
which was then used to calculate the relative slope 
of each curve obtained in the presence of the 
inhibitor, as described under Methods. The relative 
slopes were plotted by the Lineweaver-Burk plots 
using the Sigma Plot kinetics software (Fig. 4).  
The data in Fig. 4A indicate that the inhibition of 
Dox efflux by H 33342 is characteristic of 
competitive inhibition; the Km of DrrAB-mediated 
Dox transport increased at increasing 
concentration of H 33342, whereas the Vmax 
remained unchanged.  These data suggest that Dox 
and H 33342 may bind to the same site in DrrAB.  
The apparent inhibition constant (Ki for H 33342) 
was found to be 0.64 µM, which corresponds well 
to the IC50 value of H 33342 (Fig 3, panel D).  
When studying the inhibition of Dox transport by 
rifampicin, a similar pattern was observed, which 
indicated a competitive inhibition between Dox 
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and rifampicin (Fig. 4C).  However, the kinetics of 
inhibition of Dox transport by verapamil showed a 
different pattern (Fig. 4B).  The Vmax decreased at 
increasing concentration of verapamil, while Km 
remained unaltered, indicating a non-competitive 
inhibition between Dox and verapmail.  These data 
suggest that verapmail may bind to both the 
unliganded DrrAB and the binary DrrAB-Dox 
complex.  The Ki value for verapamil inhibition 
was found to be 9.4 µM, which also matches well 
to the IC50 of verapamil (Fig. 3, panel D).  The 
observed competitive and non-competitive 
inhibitions of DrrAB-mediated Dox transport in 
IOVs imply that DrrAB must contain at least two 
drug binding sites.  
The DrrAB system is a multidrug 
transporter – To determine whether the DrrAB 
system can actually transport other drugs in 
addition to Dox, two substrates (H 33342 and EtBr) 
commonly used to establish the MDR phenotype 
(10,19), were tested in IOVs, as described under 
Methods.  In addition, five other fluorescent dyes 
or drugs (including Hoechst 34580, Hoechst 
33258, quinine, TMRM, and Rhodmine 123) were 
also tested.  Of these substrates, H 33342 and EtBr 
were successfully transported by the DrrAB 
system, as described below.  
H 33342 is a cell-permeable dye, which is 
fluorescent only when bound to the cell membrane 
and loses its fluorescence in aqueous environment.  
Thus a decrease in fluorescence is expected when 
H 33342 is transported by the DrrAB system from 
the membrane to the inner aqueous environment in 
the IOVs.  EtBr, on the other hand, becomes 
fluorescent when bound to DNA inside the cells.  
Therefore, DrrAB-mediated efflux of EtBr was 
studied in preloaded cells, as described under 
Methods.  EtBr efflux under this condition is 
expected to result in quenching of fluorescence.  
The data in Fig. 5 show that both H 33342 (Fig 
5A.1) and EtBr (Fig 5B.1) are transported 
efficiently by the DrrAB system.  In the case of H 
33342, the rate of transport was seen to decrease 
after an initial linear phase of transport.  This is 
likely due to depletion of H 33342 in the 
membrane and due to passive rebinding of H 
33342 to the membrane from the aqueous phase, 
as shown earlier in the case of Pgp (19).  To 
determine the kinetic parameters for the transport 
of H 33342 and EtBr, efflux of each substrate was 
analyzed at a wide range of concentrations.  The 
initial rate of H 33342 transport in DrrAB-
containing IOVs was measured between 0.1 µM 
and 2.5 µM (Fig 5A.2).  The efficiency of H 
33342 transport was calculated, as described 
earlier for Dox (Fig. 1C).  The data were plotted 
using the Michaelis-Menten equation by the Sigma 
Plot kinetics software and could be fitted to a 
hyperbola with an R
2
 of 0.90, yielding an apparent 
Km of 0.78 µM and Vmax of 16000 (a.u.).  To study 
kinetics of EtBr transport, energy-depleted cells 
were loaded with different concentrations of EtBr 
(ranging from 1 µM to 100 µM) for 1 hour, and 
efflux was initiated by addition of 20 mM glucose 
(Fig 5B.2).  The data fitted to the hyperbola 
(Michaelis-Menten equation) with an R
2
 of 0.97, 
yielding an apparent Km of 21µM and Vmax of 550 
(a.u.).  The data in Fig 5 show that both H 33342 
and EtBr are transported efficiently by the DrrAB 
system.  A comparison of the Km and Vmax values 
for transport of Dox, H 33342, and EtBr is shown 
in Fig 5, panel C.  Five other fluorescent substrates 
(Hoechst 34580, Hoechst 33258, quinine, 
tetramethylrhodamine (TMRM), and Rhodmine 
123) tested in this study were not found to be 
exported by the DrrAB system (data not shown).  
In general, the transport data agreed with the 
inhibition data shown in Fig. 3, panel D.  
Interestingly, of the three Hoechst dyes tested, 
only H 33342 was transported.  Recent studies 
showed that a certain balance between the 
hydrophobic and hydrophilic forces in the 
structure of the target substrate is essential for 
optimum efflux by Pgp (39).  Since H 33342 is the 
most amphiphilic of the three dyes, this may 
explain why DrrAB is able to preferentially 
transport H 33342 but not the other two dyes.  
DISCUSSION 
Multidrug resistance is conferred by the 
action of specialized proteins in the cell membrane 
that have the ability to carry out energy-dependent 
efflux of structurally and functionally unrelated 
hydrophobic compounds.  This phenomenon 
defies the concept of single enzyme-single 
substrate (the lock and key model), which is 
applicable to most other enzymes.  Since the 
discovery of multidrug resistance in human cancer 
cells and bacteria (40-42), two important questions 
have remained at the forefront of this field: 1) 
what is the basis of poly-specific drug recognition 
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and transport by MDR proteins? 2) How and why 
does MDR evolve?  Extensive biochemical 
analysis of Pgp (1,4,5) as well as the availability 
of three-dimensional structures of the drug-bound 
forms of Pgp, AcrB, BmrR and QacR (6,8,43,44) 
has contributed significantly to understanding the 
molecular basis of poly-specific drug binding.  
These studies indicate that the MDR proteins 
contain an extensive (and flexible) drug binding 
pocket which can accommodate multiple drugs 
simultaneously via interactions with specific 
(sometimes overlapping) aromatic and polar 
residues present in different parts of the pocket.  
The 3-D structure of Pgp, in particular, also 
provides support for the hydrophobic vacuum 
cleaner model, which was proposed early on by 
Gottesman and colleagues (7,15) to explain the 
mechanism of multidrug transport.  According to 
this model, Pgp substrates (which are primarily 
cationic, lipid soluble, planar molecules) partition 
spontaneously into the membrane and are picked 
up by Pgp directly from the membrane (instead of 
from the cytoplasm) and then removed by its 
ability to flip drugs from the inner to the outer 
leaflet.  This model, which has now been extended 
to many other MDR proteins (45), makes a clear 
distinction between the classical solute 
transporters that remove molecules from an 
aqueous compartment and the MDR proteins that 
are proposed to function as flippases (46).  A clear 
relationship between the ability of drugs to 
partition into the membrane and their binding and 
transport by Pgp has since been documented (47-
49).  Additional evidence in support of this model 
comes from 1) the ability of most MDR proteins 
studied to date to extrude the lipopilic dye H 
33342 directly from the membrane (3,19,50,51), 
thus making it an ideal molecule to establish the 
MDR phenotype and 2) the ability of many MDR 
proteins to flip-flop lipids (52-55).  Together, 
these observations led to the idea that hydrophobic 
drugs and lipids may use a common pathway or 
flipping mechanism for extrusion. 
Despite significant progress in 
understanding the basis of poly-specific drug-
binding, the origin of multidrug resistance still 
remains an enigma.  It is generally accepted that 
most of the antibiotic and drug resistance genes 
found in clinical settings have their origins in the 
environmental bacteria (1).  Indeed many 
antibiotic producing organisms contain dedicated 
export systems to protect themselves against their 
own antibiotics (56,57).  Understanding these 
systems could hold the key to unraveling the 
origin and evolution of multidrug specificity.  It is 
generally assumed that the dedicated systems 
found in producer organisms belong to the 
category of single-drug transporters as opposed to 
multi-drug transporters (2), however their 
substrate specificity has never been investigated in 
any significant detail thus providing the impetus 
for this study. 
We show for the first time that the DrrAB 
system functions as a typical multidrug transporter 
that can carry out efflux of structurally unrelated 
substrates, including Dox, EtBr and H 33342.  
Inhibition studies further demonstrate that the 
substrate range of the DrrAB system includes 
many additional substrates, such as verapamil, 
vinblastine, and rifamicin, among others.  Thus the 
substrate specificity of DrrAB overlaps with most 
other known MDR proteins, including Pgp (58-
60).  We found, however, that unlike Pgp, neither 
quinine nor rhodamine 123 serve as substrates for 
export by the DrrAB system nor did they show 
inhibition of Dox transport.  Therefore, in spite of 
the broad substrate range of DrrAB, it appears that 
the range of substrates recognized by Pgp may still 
be larger (61), implying that the ability to bind 
some of these substrates may have evolved later in 
Pgp.  Interestingly, the IC50 values varied 
significantly among different drugs, indicating the 
different binding affinities of each substrate.  The 
highest IC50 was observed for colchicine, which is 
consistent with the data previously reported for 
Pgp (47,62,63).  This may be related with low 
hydrophobicity of colchicines (64), therefore 
indicating that the ability to partition into the 
membrane may be an important factor for 
transport by both Pgp and DrrAB.   
Kinetic characterization of Dox, H 33342, 
and EtBr transport by the DrrAB system revealed 
single-site transport kinetics.  Further, the Km 
values of 0.38 µM and 0.78 µM for transport of 
Dox and H 33342, respectively, reflect high 
affinity of these substrates for the DrrAB system 
and correspond well with the Km values seen 
earlier for Dox transport by Pgp (65) and H 33342 
transport by MsbA and LmrA (10).  Interestingly, 
however, we found that the kinetic data for Dox as 
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well as H 33342 could also be fitted by the Hill 
equation (shown in Fig. 5C) providing the nHill 
value of 1.7 for Dox (R
2
 = 0.93) and 2.0 for H 
33342 (R
2
 = 0.95), which suggests co-operative 
interaction between two or more drug binding sites 
in DrrAB.  It is not clear from these data, however, 
whether both H 33342 and Dox bind to the same 
sites in the DrrAB system.  Since EtBr transport 
by DrrAB exhibited only single-site transport 
kinetics (nHill=1.1; R
2
 = 0.98) (Fig. 5C), it possibly 
interacts with only one of the Dox/Hoechst 
binding sites, or it may bind to a completely 
different site in DrrAB.  The kinetic analyses 
shown in Fig. 4 provide evidence for competitive 
inhibition of Dox transport by H 33342 and 
rifampicin and non-competitive inhibition by 
verapamil.  Therefore, we conclude that both H 
33342 and rifampicin bind to the same site(s) as 
Dox, whereas verapamil may bind to a different 
site in DrrAB.  Evidence for two or more non-
identical drug binding sites has also been obtained 
previously with MsbA (10,53), LmrA (25) and 
Pgp (10,66,67).  In Pgp, the two sites were defined 
as the H and R sites based on their preferential 
binding to H 33342 and Rhodamine, respectively 
(68).  Together, these data point towards the 
presence of two or more drug binding sites in the 
DrrAB system.  Gleaning from the knowledge 
previously gained from studies with Pgp and 
AcrB, these different drug binding sites are likely 
part of the same binding pocket in DrrB.  
However, in the absence of a crystal structure of 
the DrrAB transporter, this conclusion is only 
tentative.   
Even though the present study does not 
provide an answer to the origin of poly-specific 
drug recognition, it does indeed show that a simple 
system like DrrAB (which may be closely related 
to the ancestral system) already contains the 
ability to recognize and transport multiple 
substrates.  This leads us to conjecture that the 
ability to transport multiple drugs is an inherent 
property of a certain class of proteins that followed 
a different evolutionary path than the classical 
transporters.  This work also opens new questions 
regarding the mechanism by which the DrrAB 
system extrudes multiple hydrophobic substrates.  
The most important of these questions is whether 
this system relies on a hydrophobic vacuum 
cleaner-like mechanism and if it is capable of 
flippase action?  Doxorubicin is produced inside S. 
peucetius cells, therefore presumably the function 
of the DrrAB system is to remove it from the 
cytoplasmic compartment to the outside.  Being 
amphipathic, however, Dox could conceivably 
partition into the cell membrane and then be 
picked up by the DrrB protein directly from the 
membrane, as suggested in an early model 
proposed for AcrB function (8).  This strategy for 
its removal could also provide protection to the 
cell from the toxic effects of free Dox inside the 
cell.  The ability to transport H 33342 no doubt 
indicates that the DrrB protein can indeed extract 
this fluorescent dye directly from the membrane 
by a mechanism similar to the one used by Pgp 
and other proteins (10,19,60).  Future studies will 
therefore focus on an in-depth analysis of the 
mechanism of drug extrusion by the DrrAB 
system.  
This and previous studies on MDR 
proteins raise many other intriguing questions; for 
example, is there evolutionary relatedness between 
MDR proteins and lipid flippases?  What is the 
real difference between the single-drug and multi-
drug transporters?  What makes certain proteins 
specific for a substrate and some others multi-
specific?  What is the contribution of high 
aromatic amino acid content of the TM helices of 
MDR proteins in conferring poly-specificity?  
Since the transmembrane helices of Pgp and other 
MDR proteins, such as the bacterial BMR, are 
highly enriched in aromatic amino acids (18% and 
15.4% for Pgp and BMR, respectively) as 
compared to the single-drug transporter TetA 
(9.4%), Pawagi et al. proposed that a greater 
number of aromatic amino acids may correlate 
with a decrease in substrate specificity of a 
transporter by providing additional binding sites 
for drugs containing aromatic rings in their 
structure (69).  Moreover, it was shown that 
mutagenesis of a single residue Ser941 to Phe in 
TM11 of Pgp significantly altered its drug efflux 
profile (70).  The recent 3-D structure confirmed 
that the drug-binding pocket of Pgp is made up of 
mostly hydrophobic and aromatic residues (6).  
Interestingly, we found that the aromatic amino 
acid content of predicted TM helices of DrrB (71) 
is also relatively high (15%) which is close to the 
aromatic content of Pgp (18%) and BMR (15.4%).  
Whether this plays a role in conferring multi-
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specificity in DrrB will be determined in future 
studies by mutagenesis of specific aromatic and 
other residues in DrrB. 
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FIGURE LEGENDS 
FIGURE 1. Characterization of the DrrAB-mediated Dox efflux under in vivo and in vitro 
conditions.  (A) In vivo analysis of DrrAB-mediated Dox efflux using E. coli cells. E. coli 
LE392ΔuncIC cells containing either vector or pDX101 (DrrAB) were loaded with 10 µM Dox, and the 
whole cell Dox efflux assay was performed, as described under Methods and in ref (21).  Dox efflux was 
measured fluorometrically (exi, 480 nm; emi, 590 nm) on an Alphascan-2 spectrofluorometer (Photon 
Technology International).  Energy was provided in the form of 20 mM glucose or 20 mM succinate at 
100 seconds (marked with an arrow) and fluorescence was monitored for an additional 400 seconds.  10 
mM sodium fluoride (NaF) was added to the samples, where indicated. A.1: Curve 1, 
pDx101(DrrAB)/glucose; Curve 2, pDx101 (DrrAB)/succinate; Curve 3, pDx101 (DrrAB)/glucose/NaF; 
Curve 4, pSU2718 (vector)/glucose; Curve 5, pSU2718/succinate; Curve 6, pSU2718/glucose/NaF. A.2: 
Quantitative presentation of the Dox efflux data shown in Fig 1A.1.  The slope of the linear portion of 
each curve shown in Fig 1A.1 was calculated.  The slope of curve 1 was designated as 1.0.  Relative slope 
of each curve was then obtained by dividing the slope of the curve by the slope of curve 1.  The average 
data obtained from three independent experiments are shown in the histogram.  (B) In vitro analysis of 
DrrAB-mediated Dox efflux using inside-out membrane vesicles (IOVs). E. coli LE392ΔuncIC cells 
containing either vector or pDX101 (DrrAB) were grown to mid-log phase and induced with 0.25 mM 
IPTG at 37 °C for 3 hr.  The membrane fraction was prepared (14) and Dox efflux in DrrAB-containing 
IOVs was performed, as described under Methods. B.1: In vitro Dox efflux assay was carried out using 
250 µg IOVs in the presence of 1 µM Dox, 0.1 mg/ml creatine kinase and 5 mM creatine phosphate in 3 
ml PBS buffer, pH 7.5, as described under Methods.  Vector, Dox efflux in IOVs prepared from cells 
containing empty vector; DrrAB, Dox efflux in IOVs prepared from cells containing pDX101 (DrrAB). 
B.2:  Quantitative presentation of Dox efflux in DrrAB-containing IOVs under various conditions. 
In vitro Dox efflux assay was carried out in the presence or absence of 1 mM ATP, 1mM GTP, 1 mM Mg 
or 5 mM NADH, as described under Methods.  The initial rate of Dox efflux was determined from the 
linear slope of the fluorescence spectra between 100 s and 200 s.  The slope of the efflux curve obtained 
by incubation of the DrrAB-containing IOVs with ATP and Mg
2+
 (column 4) was designated as 1.0.  The 
relative slope for each curve was then calculated by dividing the slope of the curve by the slope of sample 
4.  The average data obtained from three independent experiments are shown in the histogram.  (C) 
Kinetic analysis of DrrAB-mediated Dox efflux in IOVs.  In vitro Dox efflux was analyzed using 250 
µg IOVs in the presence of increasing concentrations of Dox (0.1 µM to 6.0 µM) and 1 mM ATP/Mg
2+
.  
The initial linear rate of Dox efflux was determined for each curve.  The data obtained from three 
independent experiments were fitted to the Michaelis-Menten equation and plotted by SigmaPlot-Kinetics 
software using the equation for Single Substrate Format.  (D) Inhibition of DrrAB-mediated Dox efflux 
by sodium o-vanadate. In vitro Dox efflux was measured using 250 µg IOVs in the presence 1 µM Dox, 
1 mM ATP and 1 mM Mg
2+
 and increasing concentrations of Vi (0 – 100 µM).  The initial slope of the 
efflux curve obtained with 0 µM Vi was designated as 1.0.  The relative slope of each curve was 
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determined, as described under panel A.2.  The average data obtained from three independent 
experiments are shown in the histogram.  
FIGURE 2. Effect of point mutations in the NBD of DrrA on DrrAB-mediated Dox efflux in IOVs.  
(A) ClustalW alignment of the NBD of DrrA and its prokaryotic or eukaryotic homologs.  The 
conserved motifs present in the NBD are marked at the top.  A.1, alignment of the NBD of DrrA with 
proteins (MalK, Sav1866, HlyB, TAP1, TAP2, LmrC, LmrD and LmrA) from diverse ABC families.  
A.2, alignment of the NBD of DrrA with close prokaryotic homologs (belonging to the DRA family/DRR 
subfamily) (16) identified by NCBI BLAST. A.3, alignment of the NBD of DrrA with close eukaryotic 
homologs belonging to the DRA family/ABCA subfamily (16). (B) Effect of point mutations in Walker 
A, Walker B, or the Signature motif of DrrA on DrrAB-mediated Dox efflux in IOVs. E. coli 
LE392ΔuncIC cells containing either pSU2718 vector, pDX101 (drrAB in pSU2718), pDX102 (drrA 
only, in pSU2718), pDX103 (drrB only, in pSU2718) or pDX101 containing mutations of Walker A 
(G44A, G44S, K47R), Signature motif (S141R), or the Walker B region (E165Q) were induced with 
IPTG, and the IOVs were prepared, as described under Methods. The initial rate of Dox efflux was 
determined for each sample, and the relative slopes were calculated, as described for Fig. 1. The average 
data obtained from three independent experiments are shown in the histogram. (C) Effect of point 
mutations in the Switch motif of DrrA on DrrAB-mediated Dox efflux in IOVs.  E. coli 
LE392ΔuncIC cells containing either pSU2718 vector, pDX101 (drrAB in pSU2718), or pDX101 with 
mutations of the Walker B region (E165Q) or the Switch motif (Q197H, Y198R, Q197H/Y198H, 
Q197H/Y198R) were induced with IPTG, and the IOVs were prepared, as described under Methods. The 
initial rate of Dox efflux was determined for each sample, and the relative slopes were calculated, as 
described for Fig. 1.  The data presented are averages of three independent experiments.  Error bars 
represent standard deviation.  (D) Effect of point mutations in the Switch motif of DrrA on DrrAB-
mediated ATPase activity in IOVs.  IOV samples from Fig. 2(C) were subjected to the NADH-coupled 
ATPase activity assay, as described under Methods.  The relative ATPase activity of each sample was 
obtained by dividing the activity of each sample by the activity of wild type.  The data presented are 
averages of two independent experiments.  Error bars represent standard deviation. (E) Summary of the 
ATPase activity and Dox efflux activity of wild type DrrAB and Switch motif mutants. 
FIGURE 3.  Inhibition of the DrrAB-mediated Dox efflux by known MDR substrates.  Dox efflux 
was measured using 250 µg IOVs in the presence 1 µM Dox and increasing concentrations of the 
inhibitory substrate in 3ml PBS, pH 7.5.  The initial linear rate (100 s - 200 s) of Dox efflux was 
determined after addition of 1mM ATP/Mg
2+
.  The slope of the efflux curve obtained at 0 concentration 
of inhibitor was designated as 1.0.  The relative slope of each curve was then determined.  The average 
slopes resulting from three independent repeats were plotted by Sigma Plot software using ‘scatter plot 
with error bars’, and IC50 values were determined. (A) Kinetic analysis of the inhibitory effect of H 
33342 on Dox efflux activity.  The experimental conditions were the same as described above.  The 
assay was carried out in the presence of increasing concentrations of H 33342 ranging from 0 – 1.6 µM.  
(B) Kinetic analysis of the inhibitory effect of verapamil.  The experimental conditions were the same 
as for Fig. 3(A), except that the concentration of verapamil ranged from 0 µM to 100 µM.  (C) Kinetic 
analysis of the inhibitory effect of Rifampicin.  The experimental conditions were the same as for Fig. 
3(A), except that the concentration of rifampicin ranged from 0 µM to 75 µM.   (D) A table showing 
summary of the IC50 values.  Kinetic analysis of the inhibitory effect of various drugs on DrrAB-
mediated in vitro Dox efflux was determined, as described above for panels 3A-C.   The IC50 values were 
calculated as described under Methods. 
FIGURE 4. Kinetic characterization of the inhibition of DrrAB-mediated Dox efflux by H 33342, 
verapamil or rifampicin.  The kinetics of DrrAB-mediated Dox efflux was determined in the presence of 
fixed concentrations of inhibitor, as shown in panels 4A-C.  (A) Competitive inhibition by H 33342.  
DrrAB-mediated Dox efflux was studied at four different concentrations of Dox (0.25, 0.5, 0.75 and 1.0 
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µM) in the presence of a fixed concentration of H33342.  In total, four different concentrations of H 
33342 (0, 0.2, 0.6, 0.8 µM) were studied.  The rate of Dox transport obtained with 1 µM Dox and 0 µM H 
33342 was designated as 1.0.  The relative rates were then calculated for each efflux curve, and the data 
were plotted by Lineweaver-Burk plot using Sigma Plot- Kinetics software in Single Substrate – Single 
Inhibitor Kinetics Format.  The error bars represent three separate experiments.  The type of inhibition 
was determined based on the rank of both AICc and R
2
. (B) Non-competitive inhibition by verapamil.  
The experiment was performed as described under panel (A).  Four different concentrations of verapamil 
(0, 3.5,7, 14 µM) were used. (C) Competitive inhibition by rifampicin.  The experiment was performed 
as described under panel (A). Four different concentrations of rifampicin (0, 5, 10, 20 µM) were used.  
(D) Summary of the kinetics constants obtained for inhibition of Dox efflux byH 33342, verapamil 
and rifampicin.   
FIGURE 5. The DrrAB system forms a multidrug transporter. (A.1) DrrAB-mediated H 33342 
efflux in IOVs.  The E. coli inside-out membrane vesicles were prepared, as described under Methods.  
250 µg IOVs were mixed with 0.5 µM H 33342, 0.1 mg/ml creatine kinase and 5 mM creatine phosphate 
in 3ml PBS buffer, pH 7.4.  The fluorescence spectra were recorded on an Alphascan-2-
spectrofluorometer with excitation of 355 nm and emission of 457 nm.  After 100 s, the detection was 
paused, and 1mM Mg
2+
 and 1mM ATP, pH 7.5 were added into the reaction.  The detection was 
continued for additional 250 s.  Vector, IOVs prepared from cells containing empty vector; DrrAB, IOVs 
prepared from cells expressing DrrAB.  (A.2) Kinetic analysis of DrrAB-mediated H 33342 efflux in 
IOVs.  The experimental conditions were the same as described under A.1 above.  However, H 33342 
efflux was analyzed at concentrations ranging between 0.1 µM to 2.5 µM. The initial (between 100 s-200 
s) linear rate of H 33342 efflux was determined.  The data obtained from three independent experiments 
were fitted by the Michaelis-Menten equation using Sigma Plot – Kinetics software in Single Substrate 
Kinetics Format. (B.1) DrrAB-mediated EtBr efflux in E. coli cells.  E. coli cells containing empty 
vector or DrrAB were loaded with 25 µM EtBr for 1 hr at 37 °C.  Energy was provided in the form of 20 
mM glucose, and EtBr efflux was measured, as described under Methods.  (B.2) Kinetic analysis of 
DrrAB-mediated EtBr Efflux in E. coli cells.  The experimental conditions were the same as described 
under B.1 above.  However, EtBr efflux was analyzed at concentrations ranging between 1 µM to 100 
µM.  The steady-state linear rate of EtBr efflux was determined.  The data obtained from three 
independent experiments were fitted by the Michaelis-Menten equation using Sigma Plot – Kinetics 
software in Single Substrate Kinetics Format. (C) Summary of the kinetic parameters obtained by 
using Michaelis-Menten or Hill equation for DrrAB-mediated Dox, H33342, and EtBr efflux.  
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TABLE 1. Bacterial strain and plasmids 
 
 
 
 
 
                 Name          Description        Reference 
               Bacterial Strains or Plasmid 
LE392 ΔuncIC supE44 supF58 hsdR514 galK2 galT22 metB1 trpR55 lacY1  Δ 
uncIC 
(22) 
pSU2718 Cloning vector, pACYC184 derivative, Cm
r
 (17) 
pDX101 drrAB in pSU2718, Cm
r
 (17) 
pDX102 drrA in pSU2718, Cm
r
 (17) 
pDX103 drrB in pSU2718, Cm
r
 (17) 
pDX101(G44A) drrAB in pSU2718 with mutation of Gly
44
 to Ala
44
 in the 
Walker A domain of drrA 
(31) 
pDX101(G44S) drrAB in pSU2718 with mutation of Gly
44
 to Ser
44
  in the 
Walker A domain of drrA 
(31) 
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Figure 2 
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FIGURE 3 
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FIGURE 4 
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FIGURE 5 
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